Entropy Technologies’s TG Therapeutics TGTX Stock Holding History

Entropy Technologies’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.51M	Sell	45,410 -15,005	-25%	-$447K	0.07%	335
2025 Q4	$1.8M	Buy	60,415 +53,867	+823%	+$1.76M	0.1%	268
2025 Q3	$237K	Buy	+6,548	New	+$216K	0.02%	709
2025 Q2	–	Sell	-30,859	Closed	-$1.22M	–	1016
2025 Q1	$1.22M	Buy	30,859 +22,079	+251%	+$743K	0.12%	234
2024 Q4	$264K	Sell	8,780 -22,420	-72%	-$643K	0.03%	569
2024 Q3	$730K	Buy	+31,200	New	+$681K	0.08%	340
2024 Q2	–	Sell	-53,969	Closed	-$821K	–	930
2024 Q1	$821K	Buy	53,969 +25,033	+87%	+$399K	0.09%	329
2023 Q4	$494K	Buy	+28,936	New	+$336K	0.09%	346

Other funds holding TGTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Entropy Technologies's TGTX Position: Q1 2026 in Review

Entropy Technologies reduced its TG Therapeutics (TGTX) stake by 25% in Q1 2026, selling an estimated $447K and leaving 45,410 shares worth $1.51M. The position accounts for 0.07% of the portfolio, ranked #335.

Entropy Technologies first reported a position in TGTX in Q4 2023 and has held it in 8 quarters since. The position peaked at $1.8M in Q4 2025. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

Entropy Technologies held 45,410 shares of TG Therapeutics worth $1.51M as of Q1 2026.
Entropy Technologies sold 15,005 TG Therapeutics shares in Q1 2026, an estimated $447K.
TG Therapeutics made up 0.07% of Entropy Technologies's portfolio in Q1 2026, its #335 holding.
Entropy Technologies first reported a position in TG Therapeutics in Q4 2023 and has held it in 8 quarters since.
Entropy Technologies's TG Therapeutics position peaked at $1.8M in Q4 2025.
363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Entropy Technologies's 13F filing for Q1 2026, filed 14 May 2026.